DUBLIN, March 31, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced it has received the ENERGY STAR® Partner of the Year Sustained Excellence Award for 2020, marking the seventh consecutive year it has earned ENERGY STAR®'s highest honor. The U.S. Environmental Protection Agency award recognizes Allergan for its continued leadership in energy management and efficiency.
"Allergan is proud of its longstanding commitment to increasing our energy efficiency and reducing our impact on the environment. Four years ago, we set an aggressive goal to reduce our total energy usage by 20 percent between 2015 and 2020 and today we are well on our way to achieving that goal. We congratulate our global colleagues for their tremendous efforts to support environmental responsibility, which continue to be recognized year after year," said Wayne Swanton, Executive Vice President, Global Operations at Allergan.
Prior to earning the ENERGY STAR® Sustained Excellence distinction for the last seven years, Allergan was recognized as an ENERGY STAR® Partner of the Year for two consecutive years. Additionally, Allergan's manufacturing facility in Waco, Texas was recently named an ENERGY STAR® Certified Manufacturing Plant for superior energy performance, a distinction earned only by plants in the top 25 percent of energy performance in the United States. Allergan also achieved ENERGY STAR® certification for a building located at its Irvine, California campus. Allergan has been an ENERGY STAR® partner since 1996.
For a complete list of 2020 winners and more information about ENERGY STAR's awards program, visit energystar.gov/awardwinners.
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a global pharmaceutical leader focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world. Allergan markets a portfolio of leading brands and best-in-class products primarily focused on four key therapeutic areas including medical aesthetics, eye care, central nervous system and gastroenterology. As part of its approach to delivering innovation for better patient care, Allergan has built one of the broadest pharmaceutical and device research and development pipelines in the industry.
With colleagues and commercial operations located in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.
For more information, visit Allergan's website at www.Allergan.com.
About ENERGY STAR
ENERGY STAR® is the government-backed symbol for energy efficiency, providing simple, credible, and unbiased information that consumers and businesses rely on to make well-informed decisions. Thousands of industrial, commercial, utility, state, and local organizations—including more than 40 percent of the Fortune 500 companies—rely on their partnership with EPA to deliver cost-saving energy efficiency solutions. Since 1992, ENERGY STAR and its thousands of partners helped American families and businesses save more than 4 trillion kilowatt-hours of electricity and achieve over 3.5 billion metric tons of greenhouse gas reductions. In 2018 alone, ENERGY STAR and its partners helped Americans avoid nearly $35 billion in energy costs. More background information about ENERGY STAR can be found at: energystar.gov/about and energystar.gov/numbers.
Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS®, on our financial results; risks associated with divestitures, acquisitions, mergers and joint ventures; risks related to impairments; uncertainty associated with financial projections, projected cost reductions, projected debt reduction, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2019. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.
Manisha Narasimhan, PhD
SOURCE Allergan plc